The FDA’s July 2026 Peptide Review: What PCAC Is Actually Deciding

Last updated: July 26, 2026. This page tracks the FDA Pharmacy Compounding Advisory Committee's July 2026 review of seven peptide substances. The committee has now voted; results are below. This page is updated as the record changes.

Result: the committee recommended six of seven peptides

The PCAC voted over both days. It recommended six of the seven substances for the 503A Bulk Drug Substances List and rejected one. The panel did so over the objection of the FDA's own scientific briefing, which had proposed against adding every substance on the list.

Emideltide — the FDA's name for delta sleep-inducing peptide (DSIP) — was the only substance voted down, and it was the narrowest margin of the two days at 6–7.

What the vote does and does not do. It does not make any of these an approved drug, and it does not by itself authorize compounding. The committee only advises the FDA. For a recommendation to take effect, the FDA must run formal notice-and-comment rulemaking — a process legal observers have estimated at roughly 8 to 12 months before 503A pharmacies would have unambiguous authority to compound these substances, if the agency acts at all. The FDA is not bound by the committee's vote in either direction.

None of this changes research-use-only (RUO) status. See what this does not change below.

The short version

On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) met at the agency's White Oak campus and reviewed seven peptide substances for possible inclusion on the 503A Bulk Drug Substances List. The committee's recommendations are summarized above; the sections below explain what the review was and what its outcome means.

That is a narrower question than most of the coverage suggests. The committee is not deciding whether these peptides are approved drugs. It is not deciding whether they are legal to sell. It is advising the FDA on one specific question: whether licensed pharmacies should be permitted to compound these substances into preparations for patients who have a prescription.

The committee's vote is a recommendation. The FDA is not bound by it.

What is being reviewed, and when

Per the FDA's meeting announcement and the Federal Register notice (2026-07361), the substances are split across the two days.

July 23, 2026 — 8:00 a.m. to 4:30 p.m. ET

July 24, 2026 — 8:00 a.m. to 3:50 p.m. ET

Note that the FDA is reviewing each substance in both free base and acetate salt forms. This detail is routinely dropped in secondary coverage, but it matters: the listing decision applies to specified forms of a substance, not to a compound name in the abstract.

The three things people are conflating

Most of the confusion in the current news cycle comes from collapsing three separate regulatory events into one. They are not the same, and they happen independently.

1. Removal from Category 2 — completed April 2026

In April 2026, the FDA removed a group of peptides from Category 2 of its interim bulk-substances policy — the category for substances raising significant safety concerns. This was a status change, not an endorsement and not an approval. It moved these substances into a posture where they could be formally evaluated. Nothing about removal from Category 2 authorized anything.

2. The 503A compounding review — the July 2026 vote

This is what PCAC is doing on July 23–24. Section 503A of the Federal Food, Drug, and Cosmetic Act governs compounding by licensed pharmacists. A substance placed on the 503A Bulks List may be compounded into a preparation for an identified patient with a valid prescription. This is a pharmacy pathway. It is not a retail pathway, not an over-the-counter pathway, and not a general authorization.

3. FDA drug approval

None of these seven substances is an FDA-approved drug. Approval requires a New Drug Application supported by adequate and well-controlled clinical investigations. No amount of PCAC activity changes that, and nothing scheduled in July 2026 puts any of these compounds on an approval track.

If you take one thing from this page: a favorable PCAC vote would not make any of these peptides an approved drug, and would not make them generally available. It would open a prescription-only compounding pathway.

What the FDA has said about the evidence

The FDA's own briefing position across all seven substances is consistent, and worth reading plainly. The agency has cited:

• The substances are not well-characterized
• There is little or no human evidence of effectiveness for the proposed routes of administration, which are mostly injectable
• There is insufficient human safety data, including unassessed immunogenicity risk — the possibility that the body mounts an immune response against the peptide

That is not a neutral framing from the agency. Anyone reading the July vote as a likely formality should weigh how the FDA has characterized the underlying evidence base.

The public docket

The public docket is FDA-2025-N-6895, at regulations.gov. The docket closes July 22, 2026 — the day before the meeting begins. After that, written comments are no longer accepted into the record for this review.

The meeting itself is open to the public, both at White Oak (10903 New Hampshire Ave., Bldg. 31 Conference Center, the Great Room, Rm. 1503, Silver Spring, MD 20993) and via the FDA's online teleconference and video platform.

What comes after July

Five additional substances — GHK-Cu, Melanotan II, Dihexa, LL-37, and PEG-MGF — are scheduled for a later PCAC meeting before February 2027. The July meeting is the first of at least two review cycles, not the end of the process.

What this does not change

This review concerns pharmacy compounding. It is a separate track from research-use-only (RUO) procurement, and the outcome does not alter RUO status in either direction. Materials sold for laboratory research use are not sold for human use, are not drugs, and are outside the 503A compounding framework entirely. A yes vote does not change that. A no vote does not change that either.

VOREX supplies peptides for laboratory research use only. We are covering this proceeding because it is the most misreported story in our field right now, not because it changes what we do.

Frequently asked questions

Is BPC-157 legal now?

No status changed on the day of the vote. The July 2026 PCAC recommendation (BPC-157 passed 8–6–1) is advice to the FDA about pharmacy compounding — not a legalization event and not an approval. For it to have any effect, the FDA must complete formal rulemaking, which observers estimate could take 8 to 12 months if the agency acts at all. BPC-157 is not an FDA-approved drug. Material sold for laboratory research use is sold for research use only and not for human use.

Which peptides did the FDA panel recommend?

Six of the seven received a favorable PCAC recommendation for the 503A Bulks List: BPC-157 (8–6–1), KPV (8–6–1), TB-500 (8–6–1), MOTs-C (7–5–2), Semax (8–5), and Epitalon (7–4).

Was any peptide rejected?

Yes. Emideltide — delta sleep-inducing peptide, or DSIP — was voted down 6–7, the only substance the committee declined to recommend and the narrowest vote of the two days.

Does the PCAC vote make these peptides FDA approved?

No. FDA approval requires a New Drug Application supported by adequate and well-controlled clinical investigations. The PCAC reviews whether a substance should appear on the 503A Bulk Drug Substances List for pharmacy compounding. The two processes are unrelated, and none of the seven substances is an approved drug.

What is the 503A Bulks List?

Section 503A of the Federal Food, Drug, and Cosmetic Act governs compounding by licensed pharmacists. The 503A Bulk Drug Substances List identifies bulk substances that may be used in compounding a preparation for an identified patient with a valid prescription. Placement on the list is a pharmacy pathway, not a retail or over-the-counter one.

What happened to peptides in April 2026?

The FDA removed a group of peptides from Category 2 of its interim bulk-substances policy — the category for substances raising significant safety concerns — and named seven compounds for the July 2026 PCAC review. Removal from Category 2 was a status change that allowed formal evaluation to proceed. It was not an approval or an endorsement.

When will the FDA decide?

The PCAC met July 23–24, 2026 and voted on recommendations. The committee advises the FDA; the agency is not bound by the vote and sets its own timeline. Any change would require formal notice-and-comment rulemaking, which legal observers have estimated at roughly 8 to 12 months. A further PCAC meeting covering GHK-Cu, Melanotan II, Dihexa, LL-37, and PEG-MGF is scheduled before February 2027.

Does this affect research-use-only peptides?

No. The 503A compounding framework is separate from research-use-only procurement, and the outcome of the July vote does not change RUO status in either direction. Materials supplied for laboratory research use are not drugs and are not sold for human use.

Sources

• FDA — July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee
• Federal Register — Notice of Meeting; Establishment of a Public Docket; Request for Comments (2026-07361)
• Public docket FDA-2025-N-6895, regulations.gov